查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球绝经期潮热市场 - 2023-2030年
市场调查报告书
商品编码
1290439

全球绝经期潮热市场 - 2023-2030年

Global Menopausal Hot Flashes Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概况

全球绝经期潮热市场规模在2022年达到135亿美元，预计到2030年将见证有利可图的增长，达到205亿美元。全球绝经期潮热市场在2023-2030年预测期间的复合年增长率为5.5%。

绝经期潮热市场的驱动因素包括：绝经期潮热的发病率越来越高，绝经期潮热的发病率越来越高，老龄化人口越来越多，对更年期及其相关症状的认识和了解越来越多，对女性健康的关注越来越多，治疗方案的进步，以及生活方式和偏好的改变。

更年期潮热市场存在许多制约因素和挑战，包括治疗效果有限，更年期潮热药物的副作用，治疗费用高，等等。

市场动态

绝经期潮热的发病率越来越高

绝经期潮热发病率的增加是在预测期内推动市场份额的主要因素。由于女性人口老龄化、预期寿命延长、吸烟、饮酒和垃圾食品等生活方式的改变、荷尔蒙变化、认识和寻求治疗，以及在这一人生阶段对有效管理方案的需求和对女性的支持，更年期潮热的流行率正在增加。

潮热的流行程度可能因人而异，有些人比其他人更频繁、更强烈地经历潮热。医疗保健提供者和制药公司正在不断努力开发和改进治疗方案，以减轻潮热的影响，提高经历这种常见的更年期症状的妇女的生活质量。

绝经期潮热药物的副作用

与绝经期潮热药物相关的副作用是阻碍市场份额的一个主要因素。更年期潮热药物，包括荷尔蒙和非荷尔蒙药物，都可能有潜在的副作用。值得注意的是，并非所有的人都会出现这些副作用，而且副作用的严重程度和频率也会有所不同。

COVID-19影响分析

COVID-19大流行对医疗保健的各个方面都产生了重大影响，包括对更年期潮热的管理和治疗。在大流行期间，医疗保健系统面临着巨大的挑战，包括医院不堪重负，人员短缺，以及需要将资源转用于COVID-19的应对。非紧急和选择性的医疗保健就诊，包括与更年期症状管理有关的就诊，在一些情况下被推迟或取消，导致诊断和治疗的延误。

COVID-19大流行病对全世界的个人产生了重大的心理影响。这场大流行造成的压力、焦虑和情绪困扰会加剧更年期症状，包括潮热。妇女可能需要额外的支持和资源来管理大流行病对其更年期症状的心理和情感影响。

俄罗斯-乌克兰冲突分析

俄罗斯-乌克兰冲突影响了该地区的更年期潮热市场。冲突会给受影响地区的医疗基础设施带来压力。医疗服务的中断，医疗设施的损坏，以及医护人员的流离失所都会影响医疗服务的可用性和可及性，包括更年期症状管理。

由于战争期间的压力、破坏性环境等原因，冲突直接或间接地影响了更年期潮热市场。这可能会阻碍妇女获得医疗保健服务，包括更年期潮热的诊断和治疗。

目录

第一章：方法和范围

  • 研究方法
  • 报告的研究目标和范围

第二章：定义和概述

第三章：执行摘要

  • 按产品分类的摘要
  • 按分销渠道分类
  • 按终端用户分类
  • 按地区分类

第四章：动态变化

  • 影响因素
    • 驱动因素
      • 更年期潮热发病率的增加
    • 限制因素
      • 更年期潮热药物的副作用
    • 机会
    • 影响分析

第五章：行业分析

  • 波特五力分析
  • 供应链分析
  • 价格分析
  • 监管分析

第六章：COVID-19分析

  • COVID-19的分析
    • COVID-19之前的情况
    • COVID-19期间的情况
    • 后COVID-19及未来的情况
  • 在COVID-19期间的定价动态
  • 需求-供应谱系
  • 大流行期间与市场有关的政府倡议
  • 制造商的战略倡议
  • 结语

第七章：按产品分类

  • 荷尔蒙产品
    • 雌激素
      • 普玛林
      • 薇姿
      • 薇姿-点
    • 孕激素
      • 普罗米修姆
    • 组合产品
      • 普罗旺斯
      • 杜维
  • 非荷尔蒙产品
    • 布里斯黛尔
    • 其他产品
  • 其他产品

第8章：按分销渠道分类

  • 网上商店
  • 零售店
  • 其他

第九章：按终端用户分类

  • 医院
  • 专科诊所
  • 学术和研究机构

第十章：按地区划分

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美其他地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 亚太其他地区
  • 中东和非洲

第11章 ：竞争格局

  • 竞争格局
  • 市场定位/份额分析
  • 合併和收购分析

第十二章 ：公司简介

  • Bayer AG
    • 公司概述
    • 产品组合和描述
    • 财务概况
    • 主要发展情况
  • Novartis AG
  • Pfizer Inc.
  • Novo Nordisk Corporation
  • AbbVie Inc. (Allergan Plc)
  • Hisamitsu Pharmaceutical Co. Inc.
  • Ferring Pharmaceuticals
  • Teva Pharmaceutical Industries Ltd.
  • Noven Pharmaceuticals
  • AstraZeneca

第十三章 ：附录

简介目录
Product Code: PH1623

Market Overview

The Global Menopausal Hot Flashes Market size reached US$ 13.5 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 20.5 billion by 2030. The Global Menopausal Hot Flashes Market is exhibiting at a CAGR of 5.5% during the forecast period 2023-2030.

The menopausal hot flashes market is driven by factors such as an increasing prevalence of menopausal hot flashes, growing incidence of menopausal hot flashes, a growing aging population, increasing awareness and understanding of menopause and its associated symptoms, increasing focus on women's health, advancements in treatment options, and changing lifestyles and preferences.

There are many restraints and challenges associated with the menopausal hot flashes market, including limited treatment efficacy, side effects of menopausal hot flashes drugs, high cost of the treatment, and so on.

Market Dynamics

Increasing Prevalence of Menopausal Hot Flashes

The increasing prevalence of menopausal hot flashes is a major factor driving the market share during the forecast period. The prevalence of menopausal hot flashes is increasing due to the aging women population, longer life expectancy, lifestyle changes like smoking, alcohol consumption, and junk food, hormonal changes, awareness and seeking treatment, and the need for effective management options and support for women during this stage of life.

The prevalence of hot flashes can vary among individuals, with some experiencing them more frequently and intensely than others. Healthcare providers and pharmaceutical companies are continuously working to develop and improve treatment options to alleviate the impact of hot flashes and enhance the quality of life for women experiencing this common menopausal symptom.

Side Effects of Menopausal Hot Flashes Drugs

The side effects associated with menopausal hot flashes drugs are a major factor hindering the market share. Menopausal hot flashes drugs, including hormonal and non-hormonal medications, can have potential side effects. It is important to note that not all individuals will experience these side effects, and the severity and frequency of side effects can vary.

COVID-19 Impact Analysis

The COVID-19 pandemic has significantly impacted various aspects of healthcare, including the management and treatment of menopausal hot flashes. During the pandemic, healthcare systems have faced significant challenges, including overwhelmed hospitals, staff shortages, and the need to redirect resources to the COVID-19 response. Non-urgent and elective healthcare visits, including those related to menopausal symptom management, have been postponed or canceled in some cases, leading to delays in diagnosis and treatment.

The COVID-19 pandemic has had a significant psychological impact on individuals worldwide. Stress, anxiety, and emotional disturbances resulting from the pandemic can exacerbate menopausal symptoms, including hot flashes. Women may require additional support and resources to manage the psychological and emotional effects of the pandemic on their menopausal symptoms.

Russia-Ukraine Conflict Analysis

The Russia-Ukraine conflict impacted the menopausal hot flashes market in the region. The conflict can strain the healthcare infrastructure in the affected regions. Disruptions in healthcare services, damaged medical facilities, and displacement of healthcare professionals can affect the availability and accessibility of healthcare, including menopausal symptom management.

The conflict, directly and indirectly, affected the menopausal hot flashes market due to the stress, disruptive environment during the war, and so on. This may hamper the women's access to healthcare services, including diagnosis and treatment of menopausal hot flashes.

Segment Analysis

The Global Menopausal Hot Flashes Market is segmented based on product, distribution channel, end-user, and region.

Hormonal Products are Expected to Dominate the Market Share

hormonal products are expected to dominate the market share, accounting for 47.2% during the forecast period. Hormonal products, such as estrogen therapy, progesterone therapy, or combined estrogen-progestin therapy, have been widely used for many years to manage menopausal symptoms, including hot flashes. These products work by supplementing the declining estrogen levels in the body during menopause, which can help alleviate hot flashes and other associated symptoms.

Hormonal products are often considered the most effective treatment option for menopausal hot flashes, providing significant relief for many women. They are available in various formulations, including oral tablets, patches, creams, gels, and vaginal rings, offering flexibility based on individual needs.

Geographical Analysis

North America Holds the Largest Market Share during the forecast period

North America holds the largest market share of 41.5% during the forecast period due to rising demand for menopausal hot flashes treatment. North America, which includes the United States and Canada, has a significant population of women in the menopausal age range, contributing to the demand for effective management of menopausal symptoms, including hot flashes.

Competitive Landscape

The major global players in the market include: Bayer AG, Novartis AG, Pfizer Inc, Novo Nordisk Corporation, AbbVie Inc. (Allergan Plc), Hisamitsu Pharmaceutical Co. Inc., Ferring Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Noven Pharmaceuticals, and AstraZeneca.

Why Purchase the Report?

  • To visualize the Global Menopausal Hot Flashes Market segmentation based on product, distribution channel, end-user, and region and understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of menopausal hot flashes market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The Global Menopausal Hot Flashes Market Report Would Provide Approximately 54 Tables, 46 Figures And 195 pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product
  • 3.2. Snippet by Distribution Channel
  • 3.3. Snippet by End-User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Prevalence of menopausal hot flashes
    • 4.1.2. Restraints
      • 4.1.2.1. Side effects of menopausal hot flashes drugs
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Post COVID-19 & Future Scenario
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Product

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 7.1.2. Market Attractiveness Index, By Product
  • 7.2. Hormonal Products*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 7.2.3. Estrogen
      • 7.2.3.1. Premarin
      • 7.2.3.2. Vivelle
      • 7.2.3.3. Vivelle-Dot
    • 7.2.4. Progesterone
      • 7.2.4.1. Prometrium
    • 7.2.5. Combination Products
      • 7.2.5.1. Prempro
      • 7.2.5.2. Duavee
  • 7.3. Non-Hormonal Products
      • 7.3.1.1. Brisdelle
      • 7.3.1.2. Others
  • 7.4. Others

8. By Distribution Channel

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 8.1.2. Market Attractiveness Index, By Distribution Channel
  • 8.2. Online Stores*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Retail outlets
  • 8.4. Others

9. By End-User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.1.2. Market Attractiveness Index, By End-User
  • 9.2. Hospitals*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Specialty Clinics
  • 9.4. Academic & Research Institutes

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. The UK
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Bayer AG*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Novartis AG
  • 12.3. Pfizer Inc.
  • 12.4. Novo Nordisk Corporation
  • 12.5. AbbVie Inc. (Allergan Plc)
  • 12.6. Hisamitsu Pharmaceutical Co. Inc.
  • 12.7. Ferring Pharmaceuticals
  • 12.8. Teva Pharmaceutical Industries Ltd.
  • 12.9. Noven Pharmaceuticals
  • 12.10. AstraZeneca

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us